Last reviewed · How we verify
Fondaparinux - UFH indicated
Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, preventing thrombin generation and blood clot formation.
Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, preventing thrombin generation and blood clot formation. Used for Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction), Venous thromboembolism prophylaxis in orthopedic surgery patients, Treatment of acute deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | Fondaparinux - UFH indicated |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa (Coagulation Factor X, activated form) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Fondaparinux is a synthetic pentasaccharide that binds to antithrombin III, potentiating its inhibition of Factor Xa. By blocking Factor Xa activity, it interrupts the intrinsic and common pathways of the coagulation cascade, preventing the amplification phase of thrombin generation. This results in anticoagulation without direct thrombin inhibition, distinguishing it from unfractionated heparin (UFH) which inhibits both Factor Xa and thrombin.
Approved indications
- Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction)
- Venous thromboembolism prophylaxis in orthopedic surgery patients
- Treatment of acute deep vein thrombosis and pulmonary embolism
Common side effects
- Bleeding (major and minor)
- Thrombocytopenia
- Injection site reactions
- Anemia
Key clinical trials
- Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (PHASE4)
- OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fondaparinux - UFH indicated CI brief — competitive landscape report
- Fondaparinux - UFH indicated updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI